OLMESARTAN MEDOXOMIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Olmesartan Medoxomil, and what generic alternatives are available?
Olmesartan Medoxomil is a drug marketed by Accord Hlthcare, Alembic, Alkem Labs Ltd, Amneal, Aurobindo Pharma, Chartwell Rx, Glenmark Pharms Ltd, Inventia, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, Micro Labs, MSN, Prinston Inc, Qilu, Rising, Sandoz, Sciegen Pharms Inc, Sunshine, Teva Pharms Usa, Torrent, Umedica, Zydus Pharms, Natco Pharma Usa, and Endo Operations. and is included in thirty-six NDAs.
The generic ingredient in OLMESARTAN MEDOXOMIL is amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil. There are fifty drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OLMESARTAN MEDOXOMIL?
- What are the global sales for OLMESARTAN MEDOXOMIL?
- What is Average Wholesale Price for OLMESARTAN MEDOXOMIL?
Summary for OLMESARTAN MEDOXOMIL
| US Patents: | 0 |
| Applicants: | 25 |
| NDAs: | 36 |
| Finished Product Suppliers / Packagers: | 28 |
| Raw Ingredient (Bulk) Api Vendors: | 133 |
| Clinical Trials: | 80 |
| Patent Applications: | 4,600 |
| Drug Prices: | Drug price information for OLMESARTAN MEDOXOMIL |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for OLMESARTAN MEDOXOMIL |
| What excipients (inactive ingredients) are in OLMESARTAN MEDOXOMIL? | OLMESARTAN MEDOXOMIL excipients list |
| DailyMed Link: | OLMESARTAN MEDOXOMIL at DailyMed |
Recent Clinical Trials for OLMESARTAN MEDOXOMIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| EMS | Phase 3 |
| Seoul National University Bundang Hospital | Phase 4 |
| Shenzhen People's Hospital | Phase 2 |
Pharmacology for OLMESARTAN MEDOXOMIL
| Drug Class | Angiotensin 2 Receptor Blocker |
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for OLMESARTAN MEDOXOMIL
Anatomical Therapeutic Chemical (ATC) Classes for OLMESARTAN MEDOXOMIL
Paragraph IV (Patent) Challenges for OLMESARTAN MEDOXOMIL
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| BENICAR | Tablets | olmesartan medoxomil | 5 mg, 20 mg and 40 mg | 021286 | 1 | 2006-04-25 |
US Patents and Regulatory Information for OLMESARTAN MEDOXOMIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 209281-003 | Feb 7, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Endo Operations | OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 206137-002 | Oct 26, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Prinston Inc | OLMESARTAN MEDOXOMIL | olmesartan medoxomil | TABLET;ORAL | 206720-002 | Dec 2, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Macleods Pharms Ltd | OLMESARTAN MEDOXOMIL | olmesartan medoxomil | TABLET;ORAL | 204814-002 | Apr 24, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
